Efficacy and safety of everolimus to SAve REnal Function (SAREFU) in long term heart transplanted patients

Trial Profile

Efficacy and safety of everolimus to SAve REnal Function (SAREFU) in long term heart transplanted patients

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Aug 2015

At a glance

  • Drugs Everolimus (Primary) ; ACE inhibitors; Ciclosporin
  • Indications Heart transplant rejection
  • Focus Adverse reactions
  • Acronyms SAREFU
  • Most Recent Events

    • 27 Apr 2013 Results at 5 years presented at the 33rd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
    • 14 Apr 2011 Three-year results presented at the 31st Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
    • 05 May 2010 Two-year primary endpoint results presented at the American Transplant Congress -- 10th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation (ATC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top